Readministration of adenoviral gene delivery to dopamine neurons

An approach currently being explored as treatment for Parkinson's disease is gene therapy. An important question concerns the duration of transgene expression in dopamine neurons and the issues of vector persistence, neuronal damage and the feasibility of readministering vector to the same neur...

Full description

Saved in:
Bibliographic Details
Published inNeuroreport Vol. 18; no. 15; p. 1609
Main Authors Gonzalez, Sarah C, McMenamin, Margaret M, Charlton, Harry M, Goodman, James, Lantos, Tibor, Simpson, Christine, Wood, Matthew J A
Format Journal Article
LanguageEnglish
Published England 08.10.2007
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:An approach currently being explored as treatment for Parkinson's disease is gene therapy. An important question concerns the duration of transgene expression in dopamine neurons and the issues of vector persistence, neuronal damage and the feasibility of readministering vector to the same neuronal population. We show, using an adenoviral vector expressing the LacZ reporter gene, that transgene expression declined over time but with minimal loss of dopamine neurons or vector DNA. Readministration of vector resulted in low levels of transgene delivery to the neurons. Moreover, the neurons to which vector had already been delivered were unable to transport the retrograde tracer fluorogold. Our findings indicate that transgene expression declined in dopamine neurons despite the persistence of virus, and the capacity to readminister vector to these neurons was limited.
ISSN:0959-4965
DOI:10.1097/WNR.0b013e3282f03fe5